177 related articles for article (PubMed ID: 35159380)
1. Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone.
Macedo TR; de Queiroz GF; Casagrande TAC; Alexandre PA; Brandão PE; Fukumasu H; Melo SR; Dagli MLZ; Pinto ACBCF; Matera JM
Cells; 2022 Feb; 11(3):. PubMed ID: 35159380
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of prognostic markers for canine mast cell tumors treated with vinblastine and prednisone.
Webster JD; Yuzbasiyan-Gurkan V; Thamm DH; Hamilton E; Kiupel M
BMC Vet Res; 2008 Aug; 4():32. PubMed ID: 18700956
[TBL] [Abstract][Full Text] [Related]
3. Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs.
Isotani M; Ishida N; Tominaga M; Tamura K; Yagihara H; Ochi S; Kato R; Kobayashi T; Fujita M; Fujino Y; Setoguchi A; Ono K; Washizu T; Bonkobara M
J Vet Intern Med; 2008; 22(4):985-8. PubMed ID: 18564222
[TBL] [Abstract][Full Text] [Related]
4. Prednisone and vinblastine chemotherapy for canine mast cell tumor--41 cases (1992-1997).
Thamm DH; Mauldin EA; Vail DM
J Vet Intern Med; 1999; 13(5):491-7. PubMed ID: 10499735
[TBL] [Abstract][Full Text] [Related]
5. c-Kit Mutation and Localization Status as Response Predictors in Mast Cell Tumors in Dogs Treated with Prednisone and Toceranib or Vinblastine.
Weishaar KM; Ehrhart EJ; Avery AC; Charles JB; Elmslie RE; Vail DM; London CA; Clifford CA; Eickhoff JC; Thamm DH
J Vet Intern Med; 2018 Jan; 32(1):394-405. PubMed ID: 29194765
[TBL] [Abstract][Full Text] [Related]
6. A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours.
Rassnick KM; Bailey DB; Russell DS; Flory AB; Kiselow MA; Intile JL; Malone EK; Balkman CE; Barnard SM
Vet Comp Oncol; 2010 Jun; 8(2):138-52. PubMed ID: 20579327
[TBL] [Abstract][Full Text] [Related]
7. A phase II clinical trial of vinorelbine in dogs with cutaneous mast cell tumors.
Grant IA; Rodriguez CO; Kent MS; Sfilgoi G; Gordon I; Davis G; Lord L; London CA
J Vet Intern Med; 2008; 22(2):388-93. PubMed ID: 18312556
[TBL] [Abstract][Full Text] [Related]
8. Adverse haematological effects of vinblastine, prednisolone and cimetidine treatment: a retrospective study in fourteen dogs with mast cell tumours.
Trumel C; Bourgès-Abella N; Touron C; Lanore D; Geffré A; Diquelou A; Guelfi JF; Braun JP
J Vet Med A Physiol Pathol Clin Med; 2005 Aug; 52(6):275-9. PubMed ID: 16050908
[TBL] [Abstract][Full Text] [Related]
9. Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases.
Thamm DH; Turek MM; Vail DM
J Vet Med Sci; 2006 Jun; 68(6):581-7. PubMed ID: 16820715
[TBL] [Abstract][Full Text] [Related]
10. The secondary KIT mutation p.Ala510Val in a cutaneous mast cell tumour carrying the activating mutation p.Asn508Ile confers resistance to masitinib in dogs.
Gentilini F; Turba ME; Dally C; Takanosu M; Kurita S; Bonkobara M
BMC Vet Res; 2020 Feb; 16(1):64. PubMed ID: 32075643
[TBL] [Abstract][Full Text] [Related]
11. Dysregulation of tyrosine kinases and use of imatinib in small animal practice.
Bonkobara M
Vet J; 2015 Aug; 205(2):180-8. PubMed ID: 25592261
[TBL] [Abstract][Full Text] [Related]
12. Pre-operative neoadjuvant vinblastine-prednisolone in canine mast cell tumours: A single-centre retrospective cohort study.
Ossowska M; Picornell JA; Finotello R; Amores-Fuster I; Tanis JB
Vet Comp Oncol; 2023 Sep; 21(3):447-459. PubMed ID: 37183272
[TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate treatment in a dog with gastrointestinal stromal tumors with a c-kit mutation.
Irie M; Takeuchi Y; Ohtake Y; Suzuki H; Nagata N; Miyoshi T; Kagawa Y; Yamagami T
J Vet Med Sci; 2015 Nov; 77(11):1535-9. PubMed ID: 26074249
[TBL] [Abstract][Full Text] [Related]
14. The tyrosine kinase inhibitor imatinib [STI571] induces regression of xenografted canine mast cell tumors in SCID mice.
Kobie K; Kawabata M; Hioki K; Tanaka A; Matsuda H; Mori T; Maruo K
Res Vet Sci; 2007 Apr; 82(2):239-41. PubMed ID: 16919303
[TBL] [Abstract][Full Text] [Related]
15. Analysis of risk factors for canine mast cell tumors based on the Kiupel and Patnaik grading system among dogs with skin tumors.
Martins AL; Carvalho FF; Mesquita JR; Gärtner F; Amorim I
Open Vet J; 2021; 11(4):619-634. PubMed ID: 35070857
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo evaluation of imatinib mesylate for induction of cell death on canine neoplastic mast cells with mutations in c-Kit exon 11 via apoptosis.
Rossi G; Bertani C; Mari S; Marini C; Renzoni G; Ogilvie G; Magi GE
Vet Res Commun; 2013 Jun; 37(2):101-8. PubMed ID: 23315207
[TBL] [Abstract][Full Text] [Related]
17. The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors.
Kiupel M; Webster JD; Kaneene JB; Miller R; Yuzbasiyan-Gurkan V
Vet Pathol; 2004 Jul; 41(4):371-7. PubMed ID: 15232137
[TBL] [Abstract][Full Text] [Related]
18. Imatinib elicited a favorable response in a dog with a mast cell tumor carrying a c-kit c.1523A>T mutation via suppression of constitutive KIT activation.
Yamada O; Kobayashi M; Sugisaki O; Ishii N; Ito K; Kuroki S; Sasaki Y; Isotani M; Ono K; Washizu T; Bonkobara M
Vet Immunol Immunopathol; 2011 Jul; 142(1-2):101-6. PubMed ID: 21561667
[TBL] [Abstract][Full Text] [Related]
19. Vinblastine/prednisolone chemotherapy leads to hematological toxicity in dogs with high-grade or metastatic mast cell tumors.
Soussa RW; Jaderberg S; Williams TL; Dobson JM
J Am Vet Med Assoc; 2024 Jun; ():1-9. PubMed ID: 38906172
[TBL] [Abstract][Full Text] [Related]
20. Vinblastine and prednisolone as adjunctive therapy for canine cutaneous mast cell tumors.
Davies DR; Wyatt KM; Jardine JE; Robertson ID; Irwin PJ
J Am Anim Hosp Assoc; 2004; 40(2):124-30. PubMed ID: 15007048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
